Q3 2025 EARNINGS CALL ELI LILLY AND COMPANY Agenda Introduction and Key Events Dave Ricks, Chair and Chief Executive Officer Q3 2025 Financial Results Lucas Montarce, Chief Financial Officer R&D Update Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer Question & Answer Session 3 2025 Q3 EARNINGS Safe Harbor Provision and Other Information This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various fact ...

Drug giant Eli Lilly is teaming up with chip designer Nvidia to build a supercomputer for AI-boosted drug discovery https://t.co/7J2LhEJn5S ...

Core Insights - Eli Lilly and Company is developing the most powerful supercomputer in the pharmaceutical industry in collaboration with NVIDIA, aimed at enhancing drug discovery and development processes [1][2][3] Group 1: Supercomputer and AI Factory - The supercomputer will serve as an "AI factory," managing the entire AI lifecycle from data ingestion to high-volume inference, utilizing over 1,000 B300 GPUs on a unified networking fabric [1][2] - This initiative is expected to enable rapid learning and iteration, allowing scientists to train AI models on millions of experiments, significantly expanding drug discovery capabilities [3][4] Group 2: Applications and Benefits - Beyond drug discovery, the supercomputer will help shorten development cycles, improve medical imaging, and enhance manufacturing processes through digital twins and robotic technologies [4][5] - The AI models developed will be accessible via Lilly TuneLab, a collaborative platform aimed at expanding access to advanced discovery tools across the biopharma ecosystem [3][4] Group 3: Strategic Vision - Lilly aims to shift from using AI as a tool to embracing it as a scientific collaborator, embedding intelligence into workflows to deepen understanding of diseases and improve patient outcomes [5] - The company is committed to sustainability, ensuring the supercomputer operates on 100% renewable electricity and utilizes existing infrastructure for cooling [5]

Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 financial results on Wednesday, November 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on November 5, 2025 at 8:00 am ET / 6 ...

When it comes to AI for drug discovery what used to take thousands of molecules in a design-make-test-iteration cycle can now be done in as few as hundreds of molecules. And what used to take six years might take less than a year now. A full life cycle here of the design-make-test cycle is designing molecules, medicines, proteins in a computer, being able to validate those in a wet lab and using that data that's generated to further train or fine-tune that initial model and prediction.And where we're seeing ...

Core Insights - Bruker Corporation has secured a $10 million order for advanced Nuclear Magnetic Resonance (NMR) instrumentation from notable research institutions, including the New York Structural Biology Center, the University of Delaware, and Northwestern University [1][2]. Group 1: Order Details - The $10 million order is aimed at enhancing research capabilities in drug discovery and disease biology [2]. - The advanced NMR instrumentation includes a fast NMR sample shuttle system, a magnetic tunnel, and an electromagnetic field cycling coil [2]. Group 2: Technical Capabilities - The NMR Relaxometry system allows for measurements of spin-lattice relaxation rate constants for various spins in biological macromolecules, including proteins and nucleic acids [3]. - The system operates across a range of magnetic fields from 100 µT to 16.4 T, facilitating advanced research [3]. Group 3: Research Implications - The new instrumentation is expected to open new time regimes for studying molecular dynamics, aiding in the understanding of biological processes and the discovery of potential new drugs for cancer and other diseases [4]. Group 4: Company Overview - Bruker Corporation specializes in developing, manufacturing, and distributing high-performance scientific instruments and analytical solutions across life sciences, applied sciences, and industrial applications [5]. - The company's product portfolio includes NMR spectrometers, mass spectrometry systems, atomic force microscopes, and preclinical imaging systems [5].

Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has executed a non-binding letter of intent to acquire Molecule.ai, an AI-driven company focused on transforming drug discovery and development [1][2] - Molecule.ai utilizes advanced machine learning models, including large language models, to enhance the accuracy and efficiency of evaluating novel molecules, thereby shortening development timelines and reducing costs [3][4] - The acquisition aims to integrate Molecule.ai's innovative platform into Shuttle's operations, enhancing its capabilities in drug-target interaction and autonomous drug discovery workflows [5][9] Acquisition Details - Shuttle will acquire all rights and interests of Molecule.ai, assuming all liabilities, with Molecule.ai having no further obligations post-closing [5][7] - The purchase price for the acquisition is set at $10 million, payable in cash and common shares of Shuttle, contingent upon the completion of certain milestones [7] Molecule.ai's Innovations - Molecule.ai's platform includes features such as rapid evaluation of chemical and biological properties, drug-target interaction modeling, and an autonomous framework for drug discovery workflows [9] - The introduction of the Agentic AI mode will enable AI agents to perform multi-step drug discovery processes, significantly reducing manual effort [6][9] Company Missions - Shuttle Pharmaceuticals focuses on improving outcomes for cancer patients undergoing radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [10] - Molecule.ai's mission is to empower researchers with next-generation tools that lower costs and improve efficiency in therapeutic development [8]

Group 1 - Bristol-Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals have formed a collaboration to utilize AI for drug discovery by pooling proprietary data [1][3] - The collaboration will contribute data from several thousand experimentally determined protein-small molecule structures to train an AI model named OpenFold3 [2][3] - The initiative employs a federated data sharing model provided by Apheris, allowing secure aggregation of diverse datasets while keeping sensitive data in its original location [2][3] Group 2 - The goal of the initiative is to enhance the accuracy of OpenFold3 in predicting interactions between proteins and small molecules, which is vital for drug discovery and development [3] - OpenFold3 is part of the AI Structural Biology Network, conducted in collaboration with the AlQuraishi Lab at Columbia University [3]

home system. I've got two of the three words. All right.Former FDA Commissioner Scott Gottlieb recently wrote an op ed in the Washington Post titled the FDA Should Copy China's Strategy to Speed Drug Discovery. He talks about how China is gaining ground in the United States in biotech, noting that its advantage is cost, not science. By cost, we mean cheaping out.Joining us right now is Doctor Scott Gottlieb. He's also a CNBC contributor, and he serves on the boards of both Illumina and Pfizer. And Scott, th ...

Core Insights - C4X Discovery Holdings Ltd has selected a pre-clinical candidate from its oral α4β7 integrin inhibitor programme aimed at treating inflammatory bowel disease (IBD), which supports once-daily dosing and has the potential to be a best-in-class therapy [2][3] Company Overview - C4X Discovery is a pioneering drug discovery company that combines scientific expertise with advanced technologies to develop next-generation oral medicines, focusing on immuno-inflammatory diseases [8] Market Potential - IBD affects over five million people globally and is projected to reach a market size of USD 47.7 billion by 2034, indicating a significant opportunity for C4X Discovery's oral α4β7 integrin inhibitor [3] Treatment Advantages - The oral α4β7 inhibitor offers a convenient treatment option that could advance ahead of biologics, potentially increasing the number of patients treated and improving patient outcomes while reducing the burden on healthcare systems [4] Pipeline and Future Plans - C4X Discovery is advancing multiple programmes, including oral α4β7 and TNFα inhibitors, and a first-in-class PAD4 programme, with plans to continue partnering discussions and generate pivotal data in the coming months [5]